TD Asset Management
LGND icon

TD Asset Management’s Ligand Pharmaceuticals LGND Stock Holding History

TD Asset Management’s Portfolio LGND Stock Details LGND Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q1 		– Sell
-12,664
Closed -$803K – 1409
2016
Q4 		$803K Sell
12,664
-2,404
-16% -$152K ﹤0.01% 1066
2016
Q3 		$959K Sell
15,068
-161
-1% -$11.8K ﹤0.01% 1020
2016
Q2 		$1.13M Sell
15,229
-160
-1% -$11.9K ﹤0.01% 942
2016
Q1 		$1.03M Sell
15,389
-801
-5% -$48.7K ﹤0.01% 956
2015
Q4 		$1.09M Hold
16,190
– – ﹤0.01% 938
2015
Q3 		$865K Buy
16,190
+320
+2% +$19.4K ﹤0.01% 952
2015
Q2 		$999K Buy
+15,870
New +$866K ﹤0.01% 956

Other funds holding LGND

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
William Blair Investment Management
William Blair Investment Management Chicago, Illinois $30.3B AUM 33.75% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
SCM
Scopia Capital Management New York $146M AUM 25.93% 1-Year Est. Return
DMK
David M. Knott $275M AUM 59.23% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
CCMLC
Cardinal Capital Management LLC (Connecticut) Greenwich, Connecticut $365M AUM 18.32% 1-Year Est. Return
Victory Capital Management
Victory Capital Management San Antonio, Texas $156B AUM 27.51% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return

TD Asset Management's LGND Position: Q1 2017 in Review

TD Asset Management sold out of Ligand Pharmaceuticals (LGND) in Q1 2017, closing a stake of 12,664 shares — an estimated $803K sold.

TD Asset Management first reported a position in LGND in Q2 2015 and held it in 7 quarters. The position peaked at $1.13M in Q2 2016. 256 funds tracked by Wall St. Rank hold LGND as of Q1 2017.

  • TD Asset Management reported no remaining Ligand Pharmaceuticals position as of Q1 2017 after selling out during the quarter.
  • TD Asset Management sold 12,664 Ligand Pharmaceuticals shares in Q1 2017, an estimated $803K.
  • TD Asset Management first reported a position in Ligand Pharmaceuticals in Q2 2015 and held it in 7 quarters.
  • TD Asset Management's Ligand Pharmaceuticals position peaked at $1.13M in Q2 2016.
  • 256 funds tracked by Wall St. Rank held Ligand Pharmaceuticals as of Q1 2017.

Based on TD Asset Management's 13F filing for Q1 2017, filed 5 May 2017.